021-51111890
购物车（）
sales@molnova.cn
ARC 239 dihydrochloride
CAS No. 55974-42-0
ARC 239 dihydrochloride ( ARC-239;ARC239 )
产品货号. M15036 CAS No. 55974-42-0
A potent, selective α2B adrenoceptor antagonist with pKd of 8.8, 200-fold selectivity over α2A, and α2D receptors.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥616 | 有现货 |
|
| 10MG | ￥1077 | 有现货 |
|
| 25MG | ￥2292 | 有现货 |
|
| 50MG | ￥3686 | 有现货 |
|
| 100MG | ￥5322 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ARC 239 dihydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, selective α2B adrenoceptor antagonist with pKd of 8.8, 200-fold selectivity over α2A, and α2D receptors.
-
产品描述A potent, selective α2B adrenoceptor antagonist with pKd of 8.8, 200-fold selectivity over α2A, and α2D receptors; competitively antagonizes pressor responses to adrenaline and inhibits pressor responses to noradrenaline, phenylephrine, tyramine, and dimethylphenylpiperazinium in rats and dogs.
-
同义词ARC-239;ARC239
-
通路Angiogenesis
-
靶点Adrenergic Receptor
-
受体Adrenergic Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number55974-42-0
-
分子量480.43
-
分子式C24H29N3O3.2HCl
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC1(C2=CC=CC=C2C(=O)N(C1=O)CCN3CCN(CC3)C4=CC=CC=C4OC)C.Cl.Cl
-
化学全称2-[2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mouillé P, et al. J Cardiovasc Pharmacol. 1980;2(2):175-91.
2. Bylund D, et al. J Pharmacol Exp Ther. 1988 May;245(2):600-7.
3. Bylund DB, et al. J Pharmacol Exp Ther. 1989 Nov;251(2):640-4.
2. Bylund D, et al. J Pharmacol Exp Ther. 1988 May;245(2):600-7.
3. Bylund DB, et al. J Pharmacol Exp Ther. 1989 Nov;251(2):640-4.
产品手册
关联产品
-
CL 316243
CL 316243 (BTA 243) is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM.
-
Citrulline
Citrulline is an α-amino acid.
-
Levosalbutamol
A short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
